Jun 11, 2020
Egle Therapeutics Enters Into a Corporate Strategic Research Alliance with Takeda to Uncover Novel Tumor-specific Regulatory T-cell Targets and Develop Unique Anti-Suppressor-Based Immunotherapies
Jun 02, 2020
Cellenkos® Inc. Announces FDA Clearance to Initiate Phase 1 Double- Blinded, Randomized, Placebo-Controlled Trial of Cryopreserved Cord Blood-Derived T-Regulatory Cells (CK0802) for Treatment of COVID-19 Associated Acute Respiratory Distress Syndrome
Feb 06, 2020
Sonoma Biotherapeutics launches with $40 million in Series A funding to advance regulatory T cell therapy in autoimmune and degenerative diseases
Feb 03, 2020
Nektar Therapeutics Announces Publication of Two Manuscripts on Lead Immuno-oncology Candidate, Bempegaldesleukin (Bempeg) in Nature Communications
Jan 08, 2020
Agenus Commences Phase 1 trial with AGEN1223
Nov 10, 2019
Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology
Jun 20, 2019
Medicenna Presents New Preclinical Results For its IL-2 Superkine Platform, MDNA109
Apr 02, 2019
Alligator Bioscience: New Preclinical Data for ATOR-1144 Demonstrate Potential for Activation of Both the Innate and the Adaptive Immune System, as well as Direct Anti-tumor Effects
Mar 21, 2019
BioInvent Unveils Broad Anti-TNFR2 Program to Treat Solid Tumors
Dec 03, 2018
Sangamo Announces Completion Of TxCell Acquisition
Oct 09, 2018
Oblique Therapeutics Present Tumor Growth Inhibition and Treg-lowering Data for OT-1096 in Humanized Mouse TNBC Model at Oncology Congress ESMO
Aug 01, 2018
Epigenetic Immune Cell Diagnostic Tool Shows Promise In Detecting Severe Immune Diseases Not Currently Identified In Newborn Screenings
Jul 30, 2018
OncoSec Appoints Robert W. Ashworth, Ph.D. as Vice President, Regulatory
Jul 23, 2018
Sangamo Therapeutics to Acquire TxCell
May 21, 2018
AngioMune(TM) Universal Donor T Regulatory Cell Product Effectively Reverses Cardiac Damage in Animal Models of Heart Disease
May 08, 2018
Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus
Feb 06, 2018
Compugen Announces Publication of the Discovery of ILDR2 as a Novel Immune Checkpoint and Its Use for the Treatment of Autoimmune Diseases in Two Back-to-Back Papers in The Journal of Immunology
Nov 07, 2017
Nektar Therapeutics Presents Preclinical Data on NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 2017 American College of Rheumatology Annual Meeting
Oct 31, 2017
BioLife Solutions and SAVSU Providing Enhanced Cold Chain Technologies for 8 UCSF Clinical Trials of Treg Cell Therapies
Sep 19, 2017
New Review Considers Selective Targeting of T and B Cell Populations by Alemtuzumab in the Treatment of Multiple Sclerosis